Pathology of multiple myeloma

Current Diagnostic Pathology

Volumn 9, Issue 5, 2003, Pages 322-327

  Marion, A M Van ^a   Lokhorst, H M ^a   Tweel, J G Van Den ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Immunohistochemistry; Morphology; Multilple myeloma; Plasma cell; Prognostic factors

Indexed keywords

BONE MARROW; CANCER GROWTH; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; HUMAN; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PATHOLOGY; PLASMA CELL; PLASMACYTOSIS; PROGNOSIS; REVIEW;

EID: 0242643554     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-6053(03)00052-8     Document Type: Review

References (43)

1. Jaffe E S, Harris N L, Stein H, Vardiman J W. Tumors of Haematopoietic and Lymphoid Tissues. Pathology and Genetics. World Health Organisation Classification of Tumours. Lyon: IARC Press, 2001.
2. Kyle. Prognostic factors in multiple myeloma. Hematolog Oncol 1988; 6: 125-130.
3. Islam A, Noyes S, Henderson E S. A case of aggressive multiple myeloma with convoluted and multilobated plasma cell nuclei and no visible nucleoli. Br J Haematol 1990; 76: 306-307.
4. Buss D H, Reynolds G D, Cooper M R. Multiple myeloma associated with multilobated plasma cell nuclei. Virch Arch B Cell Pathol 1988; 55: 287-292.
5. Zukerberg L R, Ferry J A, Conlon M, Harris N L. Plasma cell myeloma with cleaved, multilobated, and monocytoid Nuclei. Am J Clin Pathol 1990; 93: 657-661.
6. Rajkumar S V, Fonseca R, Lacy M Q et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol 1999; 17: 1551-1557.
7. Frisch B, Bartl R. Biopsy interpretation of bone and bone marrow. In: Histology and Immunohistology in Paraffin and Plastic, 2nd edn. Arnold: Hodder, 1999; 310-325.
8. Van den Tweel J G, Taylor C R, Parker J W, Lukes R J. Immunoglobulin inclusions in non-Hodgkin's lymphomas. Am J Clin Pathol 1978; 69: 306-313.
9. Bain B J, Clark D M, Lampert I A. Bone Marrow Pathology, 2nd edn. Oxford: Blackwell Science, 1996.
10. Gardais J, Geneviève F, Foussard C, Delisle V, Zandecki M. Is there any significance for intracellular crystals in plasma cells from patients with monoclonal gammopathies? Eur J Haematol 2001; 67: 119-122.
11. Carter A, Hocherman I, Linn S, Cohen Y, Tatarsky I. Prognostic significance of plasma cell morphology in multiple myeloma. Cancer 1987; 60: 1060-1065.
12. Bataille R, Harousseau J-L. Multiple myeloma. N Engl J Med 1997; 336: 1657-1664.
13. Greipp P R, Leong T, Bennet J M et al. Plasmablastic morphologyan independent prognostic factor with clinical and laboratory correlates. Eastern Co-operative Oncology Group (ECOG) myeloma trial E9486. Blood 1998; 91: 2501-2507.
14. Fassas AB, Muwalla F, Berryman T et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117: 103-108.
15. Ghia P, Granziero L, Chilosi M, Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Cancer Biol 2002; 12: 149-155.
16. Lokhorst H M, Lamme T, Smet de M et al. Primary tumour cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269-2277.
17. Bloem A C, Lamme T, Smet de M et al. Long term bone marrow cultured stroma cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. Br J Haematol 1998; 100: 166-175.
18. Kuehl W M, Bergsagel P L. Multiple myeloma: evolving genetic events and host interactions. Nature Rev 2002; 2: 175-187.
19. Hideshima T, Anderson K C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Rev 2002; 2: 927-937.
20. Hayashi T, Hideshima T, Anderson K C. Review: Novel therapies for multiple myeloma. Br J Haematol 2003; 120: 10-17.
21. Yang Yang, Yaccoby S, Liu W et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100: 610-617.
22. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma-new biological insights and advances in therapy. Blood 1989; 73: 865-879.
23. Alexandrakis M G, Passam F H, Malliaraki N, Katachanakis C, Kyriakou D S, Margioris A N. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002; 325: 51-57.
24. Yaccoby S, Pearse R N, Johnson C L, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278-290.
25. San Miguel J F, Almeida J, Mateo G et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002; 99: 1853-1856.
26. Bayer-Garner I B, Sanderson R D, Dhodapkar M V, Owens R B, Wilson C S. Syndecan-1 (CD138) immmunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 2001; 14: 1052-1058.
27. Durie B G. Cellular, molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am 1992; 6: 463-477.
28. Sawyer J R, Waldron J A, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41-49.
29. Sawyer J R, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome Iq in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998; 5: 1732-1741.
30. Fonseca R, Harrington D, Oken M M et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002; 62: 715-720.
31. Laterveer L, Verdonk LF, Peeters T et al. Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma. Blood 2003; 101: 1201-1202.
32. Debes-Marun C S, Dewald G W, Bryant S et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427-436.
33. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy Jr J. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late B-cell development. Blood 2003; 101: 1128-1140.
34. Calasanz M J, Cigudosa J C, Odero M D et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlation's. Genes Chromosomes Cancer 1997; 18: 84-93.
35. Zojer N, Königsberg R, Ackermann J et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925-1930.
36. Fonseca R, Blood E, Rue M et al. Clinical and biological implications of recurrent genomic aberations in myeloma. Blood 2003; 101: 4569-4575.
37. Drach J, Ackerman J, Fritz E et al. Presence of p53 gene deletion 1 patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809.
38. Pruneri G, Carboni N, Baldini L et al. Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. Hum Pathol 2003; 34: 41-47.
39. Rasillo A, Tabernero M D, Sánchez M L et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukaemia. Cancer 2003; 97: 601-609.
40. Tarte K, De Vos J, Thykjaer T et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002; 100: 1113-1122.
41. Zhan F, Hardin J, Kordsmeier B et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and bone marrow plasma cells. Blood 2002; 99: 1745-1757.
42. Strojan P, Soba E, Lamovec J, Munda A. Extramedullary plasmacytoma: clinical and histopathological study. Int J Radiat Oncol Biol Phys 2002; 53: 692-701.
43. Dimopoulos M A, Moulopoulos L A, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000; 96: 2037-2044.